Engineered CAR-T-Derived Exosomes Co-Delivering miR-145 and Cytotoxic Proteins for Targeted Solid Tumour Therapy - PubMed
3 days ago
- #exosomes
- #CAR-T therapy
- #solid tumor treatment
- Engineered CAR-T-derived exosomes (exo-CT-145) co-deliver miR-145 and cytotoxic proteins (perforin and granzyme) for targeted solid tumor therapy.
- Exo-CT-145 retains CAR-specific surface markers and demonstrates efficacy in inhibiting proliferation, migration, and Epithelial Mesenchymal Transition (EMT) in oesophageal squamous cell carcinoma (ESCC) cells.
- In vivo, exo-CT-145 shows tumor-targeted accumulation, caspase-3 activation, EMT reversal, angiogenesis suppression, and tumor microenvironment remodeling without systemic toxicity or cytokine release syndrome (CRS).
- The study presents a synergistic nanotherapeutic approach combining antigen-specific killing and gene regulatory modulation for safer and more effective solid tumor treatment.